Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
The companies are developing three of Daiichi Sankyo's DXd antibody-drug conjugate (ADC) candidates for patients across multiple types of cancer.
Merck will pay Daiichi Sankyo $5.5 billion in the agreement, which has a total potential consideration of up to $22 billion.
The three drug candidates include patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd).
Daiichi Sankyo aims for at least 900 billion yen ($6 billion) of revenue from its oncology business in the fiscal ...